The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | CHRYSALIS-2: MET IHC as a biomarker for amivantamab-lazertinib in NSCLC
Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses findings from cohorts E and F of the CHRYSALIS-2 trial (NCT04077463), which evaluated MET immunohistochemistry (IHC) as a predictive biomarker for amivantamab and lazertinib or amivantamab monotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) after progression on osimertinib. While response rates and progression-free survival were numerically higher in MET-positive groups, prespecified validation thresholds were not achieved. The analysis highlights that amivantamab, alone or in combination, remains active in this setting. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
